Altium Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Altium Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-273,204	Closed	-$587K	–	9
2025 Q1	$587K	Sell	273,204 -231,796	-46%	-$733K	1.42%	15
2024 Q4	$1.95M	Sell	505,000 -188,000	-27%	-$1.24M	0.55%	48
2024 Q3	$4.54M	Hold	693,000	–	–	1.34%	27
2024 Q2	$5.02M	Sell	693,000 -2,000	-0.3%	-$15.3K	2.05%	20
2024 Q1	$5.28M	Buy	+695,000	New	+$5.42M	2.09%	19
2022 Q4	–	Sell	-320,000	Closed	-$1.02M	–	118
2022 Q3	$1.02M	Buy	+320,000	New	+$802K	0.38%	75
2021 Q2	–	Sell	-93,261	Closed	-$1.36M	–	147
2021 Q1	$1.36M	Hold	93,261	–	–	0.38%	95
2020 Q4	$2M	Buy	+93,261	New	+$1.87M	0.75%	63

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Altium Capital Management's LRMR Position: Q2 2025 in Review

Altium Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 273,204 shares — an estimated $587K sold.

Altium Capital Management first reported a position in LRMR in Q4 2020 and held it in 8 quarters. The position peaked at $5.28M in Q1 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

Altium Capital Management reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
Altium Capital Management sold 273,204 Larimar Therapeutics shares in Q2 2025, an estimated $587K.
Altium Capital Management first reported a position in Larimar Therapeutics in Q4 2020 and held it in 8 quarters.
Altium Capital Management's Larimar Therapeutics position peaked at $5.28M in Q1 2024.
116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.